从主业范围来看，阿拉丁主营科研试剂业务，与上海佑科同属科研用品领域，二者产业协同性较高。阿 拉丁表示，本次投资上海佑科后，双方可推出"仪器+试剂"的捆绑销售或推荐套餐，丰富公司在实验室 通用分析仪器领域的产品线，便利客户一站式采购，增加客户粘性。与此同时，公司也将利用自有的客 户资源、渠道资源、电商平台资源及在国内外的仓储资源，为上海佑科充分赋能。 2024年，上海佑科营收、净利分别为1.02亿元、2248.19万元，截至2024年末资产总额为1.62亿元，净资 产为9588.52万元(前述财务数据未经审计)。 经各方初步预估，上海佑科100%股权在市盈率法下估值为1.75亿元，较2024年末净资产增值82.51%， 对应35%股权交易价格为6125万元。阿拉丁表示，上海佑科最终估值将以截至2025年12月31日的经审计 净资产为参考依据，结合资产评估报告结果，由双方友好协商确定。 近年来，阿拉丁在以内生增长巩固既有业务竞争力的基础上，积极开展投资并购和对外合作，扩充产品 线，延伸业务链条，打造新的业绩增长点。自2023年以来，公司共完成6单投资项目，扩大了重组蛋 白、生化试剂、分子酶、蛋白印迹等领域的产品覆 ...

Group 1 - Aolide plans to raise no more than 300 million yuan through a simplified procedure for issuing shares to specific targets, with net proceeds allocated to the production base project for OLED display core materials and to supplement working capital [1] - Wanbang's subsidiary has obtained a 10-year exclusive agency for sildenafil oral suspension, which is suitable for patients with swallowing difficulties [2] - Titan Technology and its affiliate plan to jointly invest in increasing capital for its subsidiary, Micro Detection, raising its registered capital from 10 million yuan to 50 million yuan [3] Group 2 - Jindike will not issue new batches of quadrivalent influenza virus split vaccine this year, having produced approximately 1.56 million doses [4] - Aladdin intends to purchase 35% equity of Youke for 61.25 million yuan, funded by its own or raised capital [5] - Gujia Home's application for a private placement of A-shares has been approved by the Shanghai Stock Exchange [7] Group 3 - Honghe Technology's application for a private placement of A-shares has been approved by the China Securities Regulatory Commission [9] - Guangdian Yuntong has won contracts totaling 308 million yuan for the construction of an artificial intelligence application pilot base [10] - Shanghai Mechanical plans to repurchase B-shares worth no more than 278 million yuan [11] Group 4 - Weiling Co. is planning a change of control, with shares representing 7.76% of the total being transferred [14] - Jiugang Hongxing intends to invest 200 million yuan to establish a wholly-owned subsidiary focusing on high-quality special steel materials [16] - Zhongjian Technology has submitted an application for H-share listing [17] Group 5 - Sainuo Medical has received registration approval for its coronary product in Pakistan [18] - Huafeng Aluminum plans to acquire 100% equity of Huafeng Puen for 100 million yuan [20] - Fuda Co. intends to establish a wholly-owned subsidiary with an investment of 30 million yuan [22] Group 6 - Su Yan Jingshen's application for a private placement of shares has been approved by the Shanghai Stock Exchange [24] - Zhongchuang Co. has set the inquiry transfer price at 25.75 yuan per share [25] - Jinpu Garden has had a lawsuit involving 26.557 million yuan accepted by the court [29] Group 7 - ICBC has approved the appointment of Zhao Guid as vice president [30] - Betta Pharmaceuticals has had its drug registration application for ensartinib accepted [32] - Times New Materials plans to invest 6 million euros to establish a wholly-owned subsidiary in Serbia [34] Group 8 - China State Construction has appointed Chen Yong as vice president [36] - Dayang Electric plans to invest 10 million yuan to establish an industrial fund [38] - Advanced Digital has appointed Liu Zhigang as deputy general manager [39] Group 9 - Tianqi Co. plans to transfer 7% equity of Youqi Intelligent for 130 million yuan [40] - Xinguo has submitted an application for H-share issuance and listing [42] - Jinhongshun's shareholder has terminated a share reduction plan [43] Group 10 - Wanrun Co.'s actual controller plans to increase shareholding between 365 million yuan and 730 million yuan [44] - Suzhou High-tech plans to sell 47% equity of its medical device subsidiary for 604 million yuan [45] - Huayou Cobalt's subsidiary has signed a product supply agreement with Yiwei Lithium Energy for approximately 127,800 tons of materials [47] Group 11 - China Communications has won 10 important projects totaling approximately 2.539 billion yuan [49] - Nopushin plans to raise no more than 1.45 billion yuan through a private placement [50] - Yun Aluminum plans to acquire minority stakes in three subsidiaries for a total of 2.267 billion yuan [51] Group 12 - Xiamen Tungsten plans to establish a 500 million yuan merger fund with multiple parties [52] - Aotewei has signed a contract worth approximately 700 million yuan [54] - Hemai Co.'s shareholders plan to reduce their holdings by no more than 3% [56]

11月25日，阿拉丁盘中上涨2.05%，截至13:48，报12.95元/股，成交3396.51万元，换手率0.79%，总市 值43.07亿元。 资金流向方面，主力资金净流入196.49万元，大单买入848.84万元，占比24.99%，卖出652.35万元，占 比19.21%。 截至9月30日，阿拉丁股东户数1.16万，较上期减少7.17%；人均流通股28729股，较上期增加7.72%。 2025年1月-9月，阿拉丁实现营业收入4.44亿元，同比增长17.59%；归母净利润5776.03万元，同比减少 20.41%。 分红方面，阿拉丁A股上市后累计派现2.41亿元。近三年，累计派现1.50亿元。 机构持仓方面，截止2025年9月30日，阿拉丁十大流通股东中，中欧医疗健康混合A（003095）、中欧 责任投资混合A（009872）、中欧行业成长混合(LOF)A（166006）退出十大流通股东之列。 责任编辑：小浪快报 阿拉丁今年以来股价涨14.27%，近5个交易日跌3.14%，近20日涨5.46%，近60日跌17.83%。 资料显示，上海阿拉丁生化科技股份有限公司位于上海市浦东新区新金桥路36号南塔16楼，成立日 ...

Company Overview - Titan Technology Co., Ltd. is located at 89 Shilong Road, Xuhui District, Shanghai, established on October 18, 2007, and listed on October 30, 2020 [1] - The company provides integrated technical solutions for scientific services, including research reagents, biological consumables, analytical consumables, laboratory instruments, smart laboratory equipment, research information technology, specialty chemicals, and related comprehensive technical services [1] - The revenue composition of Titan Technology is as follows: research reagents 42.70%, research instruments and consumables 28.42%, specialty chemicals 26.48%, laboratory construction and research information technology 2.37%, and others 0.02% [1] Financial Performance - As of September 30, Titan Technology reported a total revenue of 1.848 billion yuan for the period from January to September 2025, a year-on-year decrease of 13.06% [2] - The net profit attributable to the parent company was 11.1678 million yuan, reflecting a year-on-year increase of 15.04% [2] - Cumulative cash dividends since the A-share listing amount to 86.6205 million yuan, with 40.1089 million yuan distributed over the past three years [3] Stock Performance - On November 20, Titan Technology's stock price decreased by 2.01%, trading at 22.92 yuan per share, with a total market capitalization of 3.769 billion yuan [1] - The stock has seen a year-to-date increase of 26.14%, but has declined by 7.99% over the last five trading days, 8.14% over the last 20 days, and 18.26% over the last 60 days [1] - As of the latest data, the number of shareholders is 9,293, an increase of 20.41% from the previous period, while the average circulating shares per person decreased by 16.95% to 17,694 shares [2] Market Activity - The net outflow of main funds was 4.5418 million yuan, with large orders buying 4.3981 million yuan (16.17% of total) and selling 8.9399 million yuan (32.87% of total) [1] - Titan Technology is categorized under the basic chemicals industry, specifically in the chemical products sector, and is associated with concepts such as buybacks, margin financing, pension concepts, scientific instruments, and electronic chemicals [1]

Core Points - Aladdin's stock price decreased by 2.04% on November 17, trading at 13.42 CNY per share with a market capitalization of 4.464 billion CNY [1] - The company has seen an 18.42% increase in stock price year-to-date, with a 1.51% rise over the last five trading days and an 11.37% increase over the last 20 days, but a 13.36% decline over the last 60 days [2] - Aladdin's main business involves the research, production, and sales of reagents, with 96.96% of revenue coming from scientific reagents [2] - As of September 30, 2025, Aladdin reported a revenue of 444 million CNY, a year-on-year increase of 17.59%, while net profit attributable to shareholders decreased by 20.41% to 57.76 million CNY [2] Financials - The company has distributed a total of 241 million CNY in dividends since its A-share listing, with 150 million CNY distributed over the last three years [3] - As of September 30, 2025, the number of shareholders decreased by 7.17% to 11,600, while the average circulating shares per person increased by 7.72% to 28,729 shares [2] Shareholder Information - The top ten circulating shareholders have seen changes, with several funds exiting the list as of September 30, 2025 [3]

Company Overview - Titan Technology Co., Ltd. is located at 89 Shilong Road, Xuhui District, Shanghai, established on October 18, 2007, and listed on October 30, 2020 [1] - The company provides integrated technical solutions for scientific services, including research reagents, biological consumables, analytical consumables, laboratory instruments, smart laboratory equipment, research information technology, specialty chemicals, and related comprehensive technical services [1] Financial Performance - For the period from January to September 2025, Titan Technology achieved operating revenue of 1.848 billion yuan, a year-on-year decrease of 13.06% [2] - The net profit attributable to the parent company was 11.1678 million yuan, representing a year-on-year increase of 15.04% [2] - Cumulative cash dividends since the A-share listing amount to 86.6205 million yuan, with 40.1089 million yuan distributed over the past three years [3] Stock Performance - As of November 12, Titan Technology's stock price decreased by 2.15%, trading at 24.13 yuan per share, with a total market capitalization of 3.968 billion yuan [1] - Year-to-date, the stock price has increased by 32.80%, with a slight increase of 0.54% over the last five trading days, but a decline of 0.33% over the last 20 days and 13.33% over the last 60 days [1] - The number of shareholders as of September 30 was 9,293, an increase of 20.41% from the previous period, while the average circulating shares per person decreased by 16.95% to 17,694 shares [2] Business Segmentation - The main business revenue composition includes: research reagents (42.70%), research instruments and consumables (28.42%), specialty chemicals (26.48%), laboratory construction and research information technology (2.37%), and others (0.02%) [1] - Titan Technology is classified under the Shenwan industry as basic chemicals - chemical products - other chemical products, and is associated with concepts such as share buybacks, margin financing, electronic chemicals, pension concepts, and scientific instruments [1]

泰坦科技所属申万行业为：基础化工-化学制品-其他化学制品。所属概念板块包括：增持回购、融资融 券、养老金概念、小盘、电子化学品等。 截至9月30日，泰坦科技股东户数9293.00，较上期增加20.41%；人均流通股17694股，较上期减少 16.95%。2025年1月-9月，泰坦科技实现营业收入18.48亿元，同比减少13.06%；归母净利润1116.78万 元，同比增长15.04%。 11月11日，泰坦科技盘中上涨2.15%，截至10:36，报24.75元/股，成交3668.25万元，换手率0.92%，总 市值40.70亿元。 资金流向方面，主力资金净流入191.92万元，大单买入891.55万元，占比24.30%，卖出699.63万元，占 比19.07%。 泰坦科技今年以来股价涨36.21%，近5个交易日涨2.87%，近20日涨3.08%，近60日跌12.36%。 资料显示，上海泰坦科技股份有限公司位于上海市徐汇区石龙路89号，成立日期2007年10月18日，上市 日期2020年10月30日，公司主营业务涉及为创新研发、生产质控实验室提供科学服务一站式技术集成解 决方案,具体包括科研试剂、生物耗材、分析耗 ...

Core Points - Aladdin's stock price increased by 2.07% on November 10, reaching 13.31 CNY per share, with a total market capitalization of 4.427 billion CNY [1] - The company reported a year-to-date stock price increase of 17.44%, with a recent 5-day increase of 3.26% and a 60-day decrease of 11.27% [1] - Aladdin's main business involves the research, production, and sales of reagents, with 96.96% of revenue coming from scientific reagents [1] Financial Performance - For the period from January to September 2025, Aladdin achieved operating revenue of 444 million CNY, representing a year-on-year growth of 17.59% [2] - The net profit attributable to the parent company was 57.76 million CNY, showing a year-on-year decrease of 20.41% [2] Shareholder Information - As of September 30, 2025, the number of Aladdin's shareholders decreased by 7.17% to 11,600, while the average circulating shares per person increased by 7.72% to 28,729 shares [2] - Since its A-share listing, Aladdin has distributed a total of 241 million CNY in dividends, with 150 million CNY distributed in the last three years [3] - Notably, some institutional investors exited the top ten circulating shareholders list as of September 30, 2025 [3]

Core Viewpoint - Titan Technology is a leading company in the domestic scientific service industry, providing integrated technical solutions for innovative research and production quality control laboratories, with a differentiated advantage in full industry chain services [1] Group 1: Business Performance - For Q3 2025, Titan Technology reported revenue of 1.848 billion yuan, ranking 23rd among 79 companies in the industry, with the industry leader, Sinochem International, generating 35.716 billion yuan [2] - The revenue composition includes research reagents at 521 million yuan (42.70%), scientific instruments and consumables at 347 million yuan (28.42%), specialty chemicals at 323 million yuan (26.48%), laboratory construction and research information at 28.9049 million yuan (2.37%), and others at 289,100 yuan (0.02%) [2] - The net profit for the same period was 2.7083 million yuan, ranking 58th in the industry, with the top performer, Hangyang Co., achieving a net profit of 850 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Titan Technology's debt-to-asset ratio was 41.14%, higher than the previous year's 40.97% and above the industry average of 34.74%, indicating relatively high debt pressure [3] - The gross profit margin for Q3 2025 was 22.15%, an increase from 19.57% in the previous year and above the industry average of 19.93%, reflecting strong profitability [3] Group 3: Management and Shareholder Information - The chairman, Xie Yingbo, received a salary of 685,600 yuan in 2024, a decrease of 42,500 yuan from 2023 [4] - The number of A-share shareholders increased by 20.41% to 9,293 as of September 30, 2025, while the average number of circulating A-shares held per household decreased by 16.95% to 17,700 [5] Group 4: Strategic Developments - Titan Technology plans to enhance R&D investment, with a projected R&D expense ratio of 5% in Q1 2025 and 6% for 2024, alongside the application for 61 new patents and software copyrights [5] - The company completed acquisitions of three firms in 2024 and established two joint ventures, expanding its product matrix [5] - A strategic shift from prioritizing scale to focusing on profit is expected to positively impact cost control and cash flow [5]

Core Viewpoint - Zhongyuan Union is a leading enterprise in the domestic cell industry, focusing on cell detection, preparation, storage, and in vitro diagnostics, with a comprehensive and differentiated advantage across the entire industry chain [1] Group 1: Business Performance - In Q3 2025, Zhongyuan Union achieved a revenue of 1.092 billion yuan, ranking 9th among 39 companies in the industry [2] - The company's main business composition includes testing reagents (410 million yuan, 58.46%), cell detection preparation and storage (186 million yuan, 26.49%), scientific research reagents (83.27 million yuan, 11.86%), gene testing (16.87 million yuan, 2.40%), and others (5.53 million yuan, 0.79%) [2] - The net profit for the same period was 99.86 million yuan, ranking 12th in the industry [2] Group 2: Financial Ratios - As of Q3 2025, Zhongyuan Union's asset-liability ratio was 29.26%, down from 30.31% year-on-year, which is higher than the industry average of 18.29% [3] - The company's gross profit margin in Q3 2025 was 69.22%, slightly down from 69.82% year-on-year, but still above the industry average of 56.20% [3] Group 3: Management and Shareholder Structure - The total compensation for General Manager Wang Hongqi was 2.3881 million yuan in 2024, an increase of 1.9688 million yuan compared to 2023 [4] - The controlling shareholder is Shenzhen Jiadao Successful Investment Enterprise (Limited Partnership), with actual controllers Chen Chunmei and Gong Hongjia [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 4.06% to 34,700 [5] - The average number of circulating A-shares held per shareholder decreased by 3.91% to 13,500 [5]